Clinical Trial Update: Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of belantamab mafodotin and lenalidomide in patients with multiple myeloma who remain minimal residual di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• Revlimid (lenalidomide)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Plasma Cell Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING